La Jolla: Jefferies Global Healthcare Conference (La Jolla) - Jun 7, 2014 - "GCS-100 CKD Phase 2 Results"; "Primary endpoint reached for 1.5mg/m2 dose"; "eGFR effect correlates with change in galectin-3"; "Multiple secondary endpoints improved and consistent with primary endpoint analysis"; "No Serious Adverse Events (SAE) and no Grade 3/4 events at 1.5mg/m2 "; "No adverse effects on hematology lab parameters"
P2 data • Renal Disease
|